Ocugen (OCGN) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -10.84% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 26.38% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 34.98% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | -2.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.07% |
| Sep 30, 2025 | 2.93% |
| Jun 30, 2025 | 11.93% |
| Mar 31, 2025 | 6.91% |
| Dec 31, 2024 | -54.68% |
| Dec 31, 2023 | -42.51% |
| Jun 30, 2023 | -12.59% |
| Mar 31, 2023 | -65.98% |
| Dec 31, 2022 | -55.66% |
| Sep 30, 2022 | 1.26% |
| Jun 30, 2022 | -82.69% |
| Mar 31, 2022 | -26.53% |
| Dec 31, 2021 | -31.56% |
| Sep 30, 2021 | -46.76% |
| Jun 30, 2021 | -91.47% |
| Mar 31, 2021 | 21.03% |
| Dec 31, 2020 | 14.26% |
| Sep 30, 2020 | -27.28% |
| Jun 30, 2020 | -43.63% |
| Mar 31, 2020 | 12.23% |
| Dec 31, 2019 | 52.75% |
| Sep 30, 2019 | -35.11% |
| Jun 30, 2019 | 23.93% |
| Mar 31, 2019 | -5.86% |
| Dec 31, 2018 | 8.42% |
| Sep 30, 2018 | 25.04% |
| Jun 30, 2018 | 21.47% |
| Mar 31, 2018 | -21.74% |
| Dec 31, 2017 | 3.40% |
| Sep 30, 2017 | 24.86% |
| Jun 30, 2017 | 22.73% |
| Mar 31, 2017 | -4.08% |